公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2010 | Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma | Omata M.; Lesmana L.A.; Tateishi R.; PEI-JER CHEN ; Lin S.-M.; Yoshida H.; Kudo M.; Lee J.M.; Choi B.I.; Poon R.T.P.; Shiina S.; ANN-LII CHENG ; Jia J.-D.; Obi S.; Han K.H.; Jafri W.; Chow P.; Lim S.G.; Chawla Y.K.; Budihusodo U.; Gani R.A.; Lesmana C.R.; Putranto T.A.; Liaw Y.F.; Sarin S.K. | Hepatology International | 881 | 860 | |
2013 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study | Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; CHIH-HUNG HSU ; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Aviña J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG | Journal of Clinical Oncology | 618 | 595 | |
2020 | Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts | Bang Y.-J.; Su W.-C.; Schuler M.; Nam D.-H.; Lim W.T.; Bauer T.M.; Azaro A.; Poon R.T.P.; Hong D.; CHIA-CHI LIN ; Akimov M.; Ghebremariam S.; Zhao S.; Giovannini M.; Ma B. | Cancer Science | 43 | 35 | |
2017 | A phase I/II multicenter study of single-agent foretinib as first-line therapy in patients with advanced hepatocellular carcinoma | Yau T.C.C.; Lencioni R.; Sukeepaisarnjaroen W.; Chao Y.; Yen C.-J.; Lausoontornsiri W.; PEI-JER CHEN ; Sanpajit T.; Camp A.; Cox D.S.; Gagnon R.C.; Liu Y.; Raffensperger K.E.; Kulkarni D.A.; Kallender H.; Ottesen L.H.; Poon R.T.P.; Bottaro D.P. | Clinical Cancer Research | 45 | 38 | |
2014 | A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma | Lim H.Y.; Heo J.; Choi H.J.; Lin C.-Y.; Yoon J.-H.; CHIUN HSU ; Rau K.-M.; Poon R.T.P.; Yeo W.; Park J.-W.; Tay M.H.; Hsieh W.-S.; Kappeler C.; Rajagopalan P.; Krissel H.; Jeffers M.; Yen C.-J.; Tak W.Y. | Clinical Cancer Research | 95 | 85 | |
2016 | Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma | ANN-LII CHENG ; Thongprasert S.; Lim H.Y.; Sukeepaisarnjaroen W.; Yang T.-S.; Wu C.-C.; Chao Y.; Chan S.L.; Kudo M.; Ikeda M.; Kang Y.-K.; Pan H.; Numata K.; Han G.; Balsara B.; Zhang Y.; Rodriguez A.-M.; Zhang Y.; Wang Y.; Poon R.T.P. | Hepatology | 72 | 68 | |
2014 | Recent advances in the prevention of hepatocellular carcinoma recurrence | LI-CHUN LU ; ANN-LII CHENG ; Poon R.T.P. | Seminars in Liver Disease | 50 | 44 | |
2013 | Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: The emerging role for radioembolization using yttrium-90 | Lau W.-Y.; Sangro B.; PEI-JER CHEN ; Cheng S.-Q.; Chow P.; Lee R.-C.; Leung T.; Han K.-H.; Poon R.T.P. | Oncology (Switzerland) | 127 | 121 |